Citadel Advisors
EPRX

Citadel Advisors’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Citadel Advisors’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.67M Buy
+230,176
New +$1.85M ﹤0.01% 6489
2025
Q3 		– Sell
-18,236
Closed -$108K – 14371
2025
Q2 		$108K Buy
18,236
+6,182
+51% +$23.7K ﹤0.01% 11278
2025
Q1 		$39.4K Buy
+12,054
New +$41.6K ﹤0.01% 12553

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $14.8B AUM 15.12% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Citadel Advisors's EPRX Position: Q1 2026 in Review

Citadel Advisors opened a new position in Eupraxia Pharmaceuticals (EPRX) in Q1 2026: 230,176 shares worth $1.67M. The stake represents ﹤0.01% of the portfolio and ranks #6489 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in EPRX as recently as Q2 2025.

Citadel Advisors first reported a position in EPRX in Q1 2025 and has held it in 3 quarters since. 54 funds tracked by Wall St. Rank hold EPRX as of Q1 2026.

  • Citadel Advisors held 230,176 shares of Eupraxia Pharmaceuticals worth $1.67M as of Q1 2026.
  • Eupraxia Pharmaceuticals was a new Citadel Advisors position in Q1 2026.
  • Eupraxia Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6489 holding.
  • Citadel Advisors first reported a position in Eupraxia Pharmaceuticals in Q1 2025 and has held it in 3 quarters since.
  • 54 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.